Peter Kleist

495 total citations
26 papers, 378 citations indexed

About

Peter Kleist is a scholar working on Public Health, Environmental and Occupational Health, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Peter Kleist has authored 26 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Public Health, Environmental and Occupational Health, 6 papers in Cardiology and Cardiovascular Medicine and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Peter Kleist's work include Biomedical Ethics and Regulation (4 papers), Ethics in Clinical Research (4 papers) and Pharmaceutical studies and practices (4 papers). Peter Kleist is often cited by papers focused on Biomedical Ethics and Regulation (4 papers), Ethics in Clinical Research (4 papers) and Pharmaceutical studies and practices (4 papers). Peter Kleist collaborates with scholars based in Germany, Switzerland and Japan. Peter Kleist's co-authors include H. Fuder, P W Lücker, E Stridde, R. Arnold, Burkhard Göke, Bernhard R. Winkelmann, Naresh Ranjith, Markus Nauck, Bernhard O. Boehm and Winfried März and has published in prestigious journals such as The Lancet, Frontiers in Pharmacology and European Journal of Clinical Pharmacology.

In The Last Decade

Peter Kleist

23 papers receiving 358 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Peter Kleist 120 80 67 58 51 26 378
Brian K. Irons 228 1.9× 106 1.3× 60 0.9× 46 0.8× 33 0.6× 34 580
Evan M. Sisson 196 1.6× 126 1.6× 96 1.4× 37 0.6× 36 0.7× 34 497
Myeong Gyu Kim 47 0.4× 86 1.1× 61 0.9× 66 1.1× 56 1.1× 66 649
Richeek Pradhan 159 1.3× 106 1.3× 69 1.0× 34 0.6× 24 0.5× 29 545
Maedeh Amini 42 0.3× 91 1.1× 105 1.6× 45 0.8× 30 0.6× 21 538
Jesús Millán Núñez-Cortés 166 1.4× 46 0.6× 145 2.2× 64 1.1× 35 0.7× 107 460
Hermes Tóros Xavier 118 1.0× 64 0.8× 106 1.6× 152 2.6× 111 2.2× 20 538
Samantha Karr 55 0.5× 80 1.0× 94 1.4× 133 2.3× 58 1.1× 10 558
Brian H. Rank 38 0.3× 72 0.9× 39 0.6× 52 0.9× 122 2.4× 14 552
Karin Hådell 74 0.6× 32 0.4× 150 2.2× 62 1.1× 43 0.8× 9 405

Countries citing papers authored by Peter Kleist

Since Specialization
Citations

This map shows the geographic impact of Peter Kleist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Kleist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Kleist more than expected).

Fields of papers citing papers by Peter Kleist

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Kleist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Kleist. The network helps show where Peter Kleist may publish in the future.

Co-authorship network of co-authors of Peter Kleist

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Kleist. A scholar is included among the top collaborators of Peter Kleist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Kleist. Peter Kleist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kleist, Peter, et al.. (2022). Mediterrane oder fettarme Ernährung zur Sekundärprävention bei koronarer Herzkrankheit?. Zeitschrift für Allgemeinmedizin. 98(12). 413–414. 1 indexed citations
2.
Ferretti, Agata, Marcello Ienca, Mark Sheehan, et al.. (2021). Ethics review of big data research: What should stay and what should be reformed?. BMC Medical Ethics. 22(1). 51–51. 53 indexed citations
3.
Bergstraesser, Eva, et al.. (2020). Deficiencies in paediatric research applications delaying ethics committee approval. Swiss Medical Weekly. 150(2526). w20267–w20267. 6 indexed citations
4.
Kleist, Peter, et al.. (2020). Development and Use of Gene Therapy Orphan Drugs—Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society. Frontiers in Medicine. 7. 608249–608249. 16 indexed citations
5.
Michaud, Pierre‐André, et al.. (2020). Including adolescents of childbearing potential in clinical trials with possible exposure to teratogenic medication: a challenge for paediatricians and researchers. Swiss Medical Weekly. 150(3940). w20333–w20333. 2 indexed citations
6.
Chan, Anthony, et al.. (2020). Linking the Declarations of Helsinki and of Taipei: Critical Challenges of Future-Oriented Research Ethics. Frontiers in Pharmacology. 11. 579714–579714. 8 indexed citations
7.
Dubois, Dominique, et al.. (2018). The Shared Ethical Responsibility of Medically and Non-medically Qualified Experts in Human Drug Development Teams. Frontiers in Pharmacology. 9. 843–843. 5 indexed citations
8.
Gnädinger, Markus & Peter Kleist. (2014). Regression zum Mittelwert. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. 14(34).
9.
Kleist, Peter. (2014). Pharmazeutische Medizin: «Transparenz schafft Vertrauen!» – oder: «Transparenz statt Vertrauen?». Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. 14(5152). 1 indexed citations
10.
Kleist, Peter. (2013). Pharmazeutische Medizin: Humanforschungsgesetz – ein Spagat zwischen Persönlichkeitsrechten und Forschungsinteressen. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. 13(5152). 3 indexed citations
11.
Kleist, Peter. (2010). Kombinierte Endpunkte. Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen. 104(3). 239–242. 1 indexed citations
12.
Kleist, Peter. (2007). Composite Endpoints for Clinical Trials. International Journal of Pharmaceutical Medicine. 21(3). 187–198. 30 indexed citations
13.
Kleist, Peter. (2006). Vier Effekte, Phänomene und Paradoxe in der Medizin. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. 6(46). 6 indexed citations
14.
Kleist, Peter. (2006). Quatre effets, phénomènes et paradoxes de la médecine. Forum Médical Suisse ‒ Swiss Medical Forum. 6(46). 2 indexed citations
15.
Kleist, Peter, et al.. (2005). Eine kurze Geschichte der klinischen Studie. Meilensteine evidenzbasierter Arzneimittelprüfungen. Schweizerische Ärztezeitung. 86(44). 2475–2482.
16.
Kleist, Peter. (2002). The Impact of Biomarkers and Surrogate End Points on Regulatory Approval of New Drugs. 2(5). 235–245. 2 indexed citations
17.
Kleist, Peter, et al.. (1997). Concomitant administration of the ?-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. European Journal of Clinical Pharmacology. 53(2). 149–152. 14 indexed citations
18.
Fuder, H., et al.. (1997). The α-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. European Journal of Clinical Pharmacology. 53(2). 153–157. 13 indexed citations
19.
Göke, Burkhard, H. Fuder, E Stridde, et al.. (1995). Voglibose (AO-128) Is an Efficient α-Glucosidase Inhibitor and Mobilizes the Endogenous GLP-1 Reserve. Digestion. 56(6). 493–501. 112 indexed citations
20.
Winkelmann, Bernhard R., et al.. (1994). Discordance of anti-ischemic and hemodynamic effects of captopril in stable coronary artery disease.. PubMed. 5(10). 829–44. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian K. Irons Breakdown of academic impact, for papers by Evan M. Sisson Breakdown of academic impact, for papers by Myeong Gyu Kim Breakdown of academic impact, for papers by Richeek Pradhan Breakdown of academic impact, for papers by Maedeh Amini Breakdown of academic impact, for papers by Jesús Millán Núñez-Cortés Breakdown of academic impact, for papers by Hermes Tóros Xavier Breakdown of academic impact, for papers by Samantha Karr Breakdown of academic impact, for papers by Brian H. Rank Breakdown of academic impact, for papers by Karin Hådell
Rankless by CCL
2026